Biomerica’s $300 Medicare Rate Boost for inFoods® Test!

Introduction

Biomerica, Inc. (NASDAQ: BMRA) – a small-cap diagnostic company specializing in gastrointestinal tests – has achieved a pivotal milestone for its flagship inFoods® IBS diagnostic test. On December 23, 2025, the Centers for Medicare & Medicaid Services (CMS) set a national Medicare reimbursement rate of $300 for the inFoods® IBS test (^[1]) (^[1]). This Medicare rate determination marks a significant commercial breakthrough, as Medicare is the largest U.S. healthcare payer and covers roughly 21% of total health expenditures (^[1]). Biomerica’s stock reacted positively to the news – shares rose around 5–8% after the announcement (^[2]) (^[3]) – reflecting investor optimism that this reimbursement will spur broader adoption of the test.

This report provides a deep dive into Biomerica’s financial profile and outlook in light of the Medicare reimbursement boost. We will review the company’s background and product strategy, dividend policy, balance sheet leverage and funding, current valuation, and the key risks and open questions facing the company as it works to commercialize inFoods® IBS nationally.

Company Overview and inFoods® IBS Test

Biomerica is a biomedical technology firm focused on developing and marketing diagnostic solutions, primarily for gastrointestinal and inflammatory diseases (^[4]). The company’s product portfolio includes at-home and point-of-care tests for conditions like colorectal disease (EZ Detect™ stool test) and H. pylori infection (hp+detect™), which generate modest revenues. In the fiscal year ended May 2023, Biomerica’s net sales were $5.3 million, down sharply from $18.9 million in the prior year due to the fade-out of one-time COVID-19 test sales (^[4]). Excluding COVID test kits, core product revenue actually grew ~15% in 2023 (^[4]), indicating some underlying demand for its legacy diagnostic products. However, with COVID sales gone, the company’s future growth hinges on successful commercialization of inFoods® IBS, its most advanced new product.

inFoods® IBS is a proprietary lab-developed test designed to identify patient-specific food triggers that exacerbate Irritable Bowel Syndrome (IBS) symptoms (^[1]). Using a simple finger-stick blood sample, the assay measures immune reactivity (IgG antibodies) to a panel of common foods, enabling physicians to tailor dietary recommendations to each IBS patient (^[4]). The aim is to move beyond trial-and-error diets and provide a precision nutrition approach for IBS, an ailment affecting an estimated 10–15% of adults (over 30 million people in the U.S.) (^[1]) (^[5]). Current IBS treatments often yield inconsistent relief, and notably no FDA-approved medications exist for IBS-M (the mixed subtype with alternating constipation/diarrhea), which accounts for about one-third of IBS cases (^[1]). This leaves a major unmet need that inFoods® IBS seeks to address.

Biomerica has backed inFoods® IBS with rigorous clinical evidence. In a multicenter double-blind, placebo-controlled trial (conducted at Mayo Clinic, Harvard’s Beth Israel Deaconess, University of Michigan, Cleveland Clinic, and others), patients who eliminated foods flagged by the inFoods test saw significantly greater symptom improvement than those on a sham diet (^[5]) (^[5]). Specifically, 59.6% of patients following the inFoods-guided diet achieved the FDA-defined target for abdominal pain reduction, versus 42% in the control group (^[2]). The effect was even more pronounced in hard-to-treat subgroups – for example, 66% of IBS-M patients in the treatment arm met the pain reduction endpoint, compared to only 29.5% of controls (^[5]). These clinically meaningful outcomes, published in the Gastroenterology journal (June 2025), provide Level 1 evidence supporting the test’s efficacy (^[1]) (^[6]). By personalizing diet management in IBS and demonstrating results comparable or superior to existing drugs (^[4]), (^[6]), inFoods® IBS offers a differentiated, non-pharmaceutical therapy option.

Medicare Reimbursement Milestone

Gaining a CMS reimbursement code and pricing is a critical step for any diagnostic test, and Biomerica cleared that hurdle in late 2025. After the AMA approved a unique CPT® Proprietary Lab Analyses (PLA) code for inFoods® IBS (effective Oct 1, 2025), CMS has now assigned a $300 payment rate under the Clinical Lab Fee Schedule, applicable for Medicare claims dated on or after Jan 1, 2026 (^[1]) (^[1]). This means Medicare will pay $300 per test for eligible patients – a substantial amount that validates the test’s economic value. Management emphasized that this pricing provides “a foundation for negotiations with private insurers,” as commercial payers often look to CMS benchmarks (^[1]) (^[2]). With over 20% of U.S. adults being of Medicare age (and a significant subset of IBS sufferers being seniors), Medicare coverage is “a critical payer” for IBS diagnostics (^[1]).

Importantly, pricing is not the same as coverage – the next step is for Biomerica and its laboratory partner to secure formal Medicare coverage determinations from Medicare Administrative Contractors in various regions (^[1]). The company indicated it will work with these contractors to attain coverage for inFoods® IBS, now that a national rate is set (^[1]). In parallel, Biomerica will leverage the $300 price point to pursue reimbursement deals with private health insurers such as Aetna, UnitedHealthcare, and Blue Cross/Blue Shield (^[1]) (^[2]). Ultimately, broad insurance coverage will be key to driving patient access and physician adoption of the test, since IBS patients are typically sensitive to out-of-pocket costs for diagnostics. Biomerica’s plan also involves scaling up distribution – they have already entered a marketing partnership with Henry Schein, Inc. (a leading medical products distributor) to promote inFoods® IBS to physicians across the U.S. (except New York State) (^[7]) (^[7]). Henry Schein’s network of 400+ medical sales reps is expected to help accelerate test uptake in primary care and GI practices (^[7]) (^[7]).

Overall, the CMS reimbursement milestone significantly boosts the commercial outlook for inFoods® IBS. As CEO Zack Irani noted, having both a dedicated billing code and established Medicare pricing puts Biomerica “well-positioned for continued commercial growth in 2026 and beyond” (^[2]). The company is moving from a pilot-launch phase (completed in 2023 with select GI clinics) to a national rollout. It has hired a specialized GI sales force and begun engaging large medical groups to adopt the test system-wide (^[8]) (^[8]). For instance, a pilot with one of the country’s largest gastroenterology groups (1,100 physicians) was completed in 2024, and that group is evaluating a potential enterprise-wide launch of inFoods® IBS across all its offices (^[8]). Such developments hint at the market penetration possible if clinical enthusiasm and reimbursement align.

Dividend Policy and Shareholder Yield

Biomerica is not a dividend-paying stock, which is common for small, growth-oriented biotech and diagnostic companies. The company has never paid cash dividends on its common stock and does not plan to do so in the foreseeable future (^[9]). Instead, any future earnings are expected to be reinvested to expand operations and drive product commercialization (^[9]). Consequently, Biomerica’s dividend yield is 0%, and investors seeking returns have to rely on stock price appreciation rather than income. Management has explicitly stated its intention to retain earnings to finance growth rather than return cash to shareholders (^[9]). This policy is sensible given Biomerica’s stage – the company is still incurring net losses (as discussed below) and needs capital to fund sales expansion and R&D. Until sustained profitability is achieved, a dividend is unlikely.

Share buybacks are also not part of Biomerica’s capital allocation currently. The firm did not repurchase any shares in the last fiscal year (^[9]). In fact, the share count has increased over time due to equity financings (detailed in the leverage section). Thus, shareholders should not expect yield from dividends or buybacks in the near term. The focus remains on reinvesting for growth, with the implicit hope that successful execution (e.g. turning inFoods® IBS into a revenue engine) will eventually be reflected in a higher stock price.

Financial Position, Leverage, and Coverage

Biomerica’s capital structure is very conservatively levered, as the company carries minimal debt. According to the latest audited balance sheet (fiscal year ended May 31, 2023), total liabilities were only about $2.73 million, consisting mostly of accounts payable and lease obligations (^[9]) (^[9]). There were no bank loans, no bonds, and no outstanding long-term debt instruments on the books. In fact, even preferred equity has been eliminated – a small 5% Series A Convertible Preferred Stock issued in 2020 was fully converted to common stock by 2021 (^[9]) (^[9]). With no interest-bearing debt, Biomerica has no interest expense and thus faces no issues with interest coverage ratios or debt maturities. The only fixed financial obligations are operating leases (mainly for facilities/equipment), totaling roughly $1.1 million in future payments as of mid-2023 (^[9]) (^[9]).

The company has primarily financed itself through equity capital and retains a positive shareholders’ equity balance. At May 31, 2023, Biomerica’s shareholders’ equity was about $11.7 million, far exceeding total liabilities (debt-to-equity is negligible) (^[9]). This reflects the influx of cash from share issuances in recent years. Notably, in March 2023 Biomerica raised $8 million gross via an underwritten public offering, selling 3.33 million shares at $2.40 each (^[10]) (^[10]). Additionally, the company periodically utilized an “at-the-market” shelf registration to sell shares into the market – approximately $5.3 million was raised through such ATM equity sales up to March 2023 (^[9]). These financings bolstered the cash reserves needed to fund the inFoods® IBS clinical trials and initial marketing.

As of August 31, 2023 (Q1 FY2024), Biomerica reported $8.0 million in cash and equivalents on hand (^[11]) (^[11]). By February 29, 2024 (Q3 FY2024), cash had declined to ~$5.3 million (^[12]) (^[12]), reflecting continued operating losses and working capital use. The company estimated that existing cash was sufficient to fund operations through at least May 2025, barring unforeseen expenses (^[12]). This runway has likely been extended somewhat by cost-cutting measures and improved margins in 2025, but Biomerica’s cash burn remains an important metric to monitor. In the most recent quarter (Q1 FY2026, quarter ended Aug 31, 2025), the operating loss was $1.1 million (^[6]) – an improvement from prior periods – and a one-time tax credit even produced a near break-even net profit for that quarter (^[6]). If the inFoods® IBS rollout succeeds in boosting revenue, the company could approach cash flow breakeven, reducing pressure to raise new capital. Indeed, management has highlighted its ongoing focus on cost control and noted that operating expenses have been trending down (~$1.5 million in Q1 FY2026, 12% lower year-on-year) (^[6]).

For now, leverage is low and financial flexibility is maintained, but Biomerica’s solvency ultimately hinges on achieving profitable operations. In the absence of debt, coverage ratios (like interest coverage or fixed-charge coverage) are not a concern – the more relevant coverage aspect is whether the company can generate sufficient gross profit to cover its operating expenses. To that end, the recent gross margin improvement to 31% (Q1 FY2026) from teens a year prior is encouraging (^[6]) (^[6]), as it reflects a higher mix of proprietary and contract manufacturing revenue. Still, net losses have accumulated (over $7 million loss in FY2023) and additional funding may be needed if substantial positive cash flow is not reached. Management acknowledges that if they cannot sustain positive cash flows, they “would be required to seek additional funding, which may not be available on favorable terms, if at all.” (^[9]) This implies potential future dilution if equity issuance is the only financing option. Investors should expect Biomerica to continue operating with an equity-funded model and minimal debt for the foreseeable future.

Valuation and Stock Performance

Biomerica’s market valuation reflects its micro-cap, pre-profit status. At the time of the Medicare reimbursement news, the company’s market capitalization was roughly $6.8 million (^[7]). This is exceptionally small – by comparison, it equates to roughly 1.3× Biomerica’s annual revenues (which have been in the $5–6 million range) (^[4]). In other words, the stock trades at about 1.3 times trailing sales, a low price-to-sales multiple that suggests the market has modest expectations for the business. The price-to-book ratio is also undemanding: with shareholders’ equity around $10–11 million, the market cap is actually below book value (P/B < 1). Such depressed multiples often indicate investor skepticism about a company’s ability to monetize its assets or reach profitability. It is not unusual for micro-cap biotech/diagnostic firms to trade at low multiples when cash is running down – essentially, the market is assigning a low probability to future success until more proof emerges.

Biomerica’s stock has been volatile and thinly traded, which is typical for a company of this size. The stock is listed on the Nasdaq Capital Market under ticker BMRA, but trading volume is relatively light, meaning share price can swing sharply on small trades (^[9]). For example, when the Henry Schein marketing partnership was announced in October 2025, BMRA shares spiked as much as +18% intraday before closing up ~5% on that day (^[7]). Similarly, the CMS reimbursement news prompted a 5–8% jump in the stock in a single session (^[2]) (^[3]). Earlier in 2024–2025, the stock price had declined into compliance trouble – falling below Nasdaq’s $1.00 minimum bid requirement – which forced Biomerica to undertake a 1-for-8 reverse stock split in April 2025 (^[13]). The reverse split shrank the outstanding share count from ~20.4 million pre-split to ~2.55 million post-split (^[13]), raising the per-share price and restoring compliance with Nasdaq listing rules (^[13]). This maneuver underscores both the volatility of the stock and management’s commitment to maintaining a Nasdaq listing (important for liquidity and credibility).

Post-split, as of late 2025, the stock has been trading in the low single digits (approximately $2–3 per share range). Given the tiny market cap, even moderate positive or negative developments can cause outsized percentage moves in the share price. Investors should be aware that BMRA is a high-risk, speculative equity at this stage. The valuation could rise dramatically if inFoods® IBS gains traction and revenue accelerates (due to the large IBS market opportunity), but conversely, any setbacks in commercialization would weigh heavily on such a small stock. At present, the valuation appears to price in a “wait-and-see” stance – the market is not paying up for future potential until clearer evidence of revenue growth and path to profitability materialize.

Risks and Red Flags

Despite the recent positive developments, Biomerica faces significant risks and uncertainties that current and prospective investors should weigh:

– Ongoing Losses and Cash Burn: The company has a history of net losses (e.g. -$7.1 million in FY2023) and, while cost cuts have narrowed the quarterly loss, Biomerica has yet to prove it can sustain profitability (^[11]) (^[11]). If revenues from inFoods® IBS ramp up slower than expected, the company could continue burning cash. Management has warned that failure to achieve profitability or positive cash flow will likely necessitate raising additional capital (^[9]). Given the micro-cap equity valuation, any new equity raise could be highly dilutive to existing shareholders, and there is no guarantee that funding will be available on favorable terms (^[9]). This dependency on external financing is a key risk.

– Reliance on inFoods® IBS Success: Biomerica is now heavily reliant on one product – the inFoods® IBS test – to drive growth. Its other product lines (EZ Detect, H. pylori tests, etc.) provide only modest baseline sales. The dramatic drop in revenue from $18.9M to $5.3M after COVID test sales ended exemplifies how limited the legacy revenue streams are (^[4]). If the IBS test fails to achieve broad market adoption, the company has limited fallback options. This concentration risk makes the investment thesis essentially a bet on inFoods® IBS’s commercial viability.

– Market Adoption and Insurance Coverage Risks: The commercial adoption of inFoods® IBS remains an open question. Changing physician behavior and standard of care in IBS management will take time. Gastroenterologists and primary care doctors may be cautious in adopting a new test unless convinced of its utility and cost-effectiveness. While the clinical trial results are strong, some skepticism might linger in the medical community given the checkered history of “food sensitivity” tests. Furthermore, insurance coverage is not yet fully secured. Medicare has set a price, but Biomerica still must obtain coverage policies from Medicare contractors (^[1]). Private insurers will each make their own decisions on coverage, which could be a slow, payer-by-payer process. There is a risk that some insurers might initially deny or restrict reimbursement for the test (for example, requiring prior authorization or proof of medical necessity) until more real-world evidence or cost-saving data is available. The timeline for broad insurance uptake is uncertain – any delays here would directly impact how quickly Biomerica can convert the test into revenue.

– Execution and Scaling Risk: Scaling up a national diagnostics launch with a small organization is challenging. Biomerica has had to build a sales infrastructure from scratch, hiring a VP of Sales and territory reps in 2024 (^[4]) (^[4]). Managing this new salesforce effectively and securing partnerships with large GI practices or hospital systems is not guaranteed. The Henry Schein marketing agreement should help, but notably it excludes New York State due to regulatory complexities (^[7]). This leaves out a major metro market (NY) until Biomerica possibly obtains separate clearance there, which is a near-term limitation. Additionally, the inFoods® IBS test is run as a lab-developed test (LDT) through a partner lab – this means volume is tied to that lab’s capacity and CLIA certifications. If demand surges, Biomerica and its partner must ensure lab throughput and logistics can scale accordingly (including test kit supply, sample handling, and results reporting systems to doctors). Operational hiccups in scaling could hurt the company’s reputation with physicians.

– Regulatory and Reimbursement Environment: While LDTs currently do not require FDA approval, there is ongoing policy debate about increasing FDA oversight of laboratory tests. Any regulatory changes that impose additional approval requirements on LDTs could complicate Biomerica’s business model or require expensive studies. On the reimbursement side, Medicare pricing can change – though the $300 rate is set for now, CMS periodically reviews and can adjust lab test fees. If utilization is lower or higher than expected or if competitive tests emerge, future reimbursement rates could be revised. Also, Medicare coverage criteria (once established) might limit testing to certain patient subgroups. These factors introduce reimbursement risk.

– Competition and Alternatives: Biomerica highlights that inFoods® IBS is unique as an IBS-specific diagnostic-guided therapy backed by a large trial (^[1]). Direct competition is limited in the IBS diagnostic space; however, they do face indirect competition from the status quo (e.g. generic elimination diets like low-FODMAP diet, or patients simply cycling through existing IBS medications). There are also many DTC “food intolerance” tests on the market (usually IgG panels) offered by various labs, albeit without IBS-specific validation. Some physicians might consider those as alternatives, even if they are less validated. In the future, larger diagnostic companies could potentially develop similar precision nutrition tests for IBS or other GI disorders, especially if Biomerica demonstrates a lucrative market. Competitors with far greater resources could pose a threat if they enter this niche (^[1]). Biomerica’s patent portfolio (19 issued patents for inFoods technology) offers some protection (^[4]), but enforcement and the emergence of substitute technologies remain uncertainties.

– Stock Volatility and Liquidity: As mentioned, BMRA stock is thinly traded and can be extremely volatile. This not only poses a risk of quick capital losses for investors, but it also could impede the company’s ability to raise equity capital at favorable prices. A large shareholder selling or any negative news can sharply depress the stock due to low trading liquidity (^[9]) (^[9]). Moreover, if the share price falls below compliance thresholds again, it might risk Nasdaq delisting (which the company narrowly avoided by executing the reverse split in 2025) (^[13]). Delisting would be a significant red flag, reducing stock liquidity and access to capital. Management will likely do everything to avoid that, but it’s a risk tied to market volatility.

In summary, Biomerica must execute nearly flawlessly in commercializing inFoods® IBS to overcome these challenges. The margin for error is small given limited cash reserves and reliance on one product. Investors should monitor how quickly the test gains coverage and adoption, as well as the company’s cash burn rate, to gauge whether these risks are being mitigated or intensifying.

Open Questions and Outlook

With 2026 on the horizon, several open questions will determine Biomerica’s trajectory in the coming quarters:

– How Quickly Will Medicare and Private Insurance Coverage Expand? Now that a Medicare price is in hand, the critical question is when Medicare will actually start paying for inFoods® IBS tests in practice. Biomerica must secure Local Coverage Determinations (LCDs) or other approval from Medicare contractors – it remains to be seen if that happens early in 2026 or takes longer. Any delays in Medicare coverage (despite pricing being set) could slow initial adoption. Similarly, how many major private insurers will agree to reimburse the test in 2026? Will we see any of the big insurers (United, Anthem, Aetna, etc.) add inFoods® IBS to their covered services next year, or will they wait for more utilization data? These coverage decisions are pivotal for unlocking the large non-Medicare patient segment (^[1]). Early traction with one or two insurers could snowball, whereas protracted holdouts would force Biomerica to rely on cash-pay or limited regional coverage, constraining growth.

– What Revenue Uptake and Financial Impact Will the IBS Test Have? Investors will be watching Biomerica’s quarterly revenues in 2026 for evidence of inflection. The company has indicated rising inFoods® IBS product sales contributed in mid-2025 on a pilot scale (^[6]). The open question is: does revenue begin to accelerate meaningfully now that full launch efforts are underway (Q1 2026 sales were $1.4M, slightly down year-on-year due to other factors) (^[6]). A major test will be whether Biomerica can, for example, double or triple its revenue run-rate over the next 12–18 months as IBS test volumes grow. Even at $300 reimbursement, widespread ordering is needed to move the needle. For instance, 1,000 tests would yield $300k in revenue; to add several millions in sales, the company needs tens of thousands of tests run per year. Achieving that kind of volume will depend on effectively reaching gastroenterologists and perhaps primary care physicians. Biomerica’s recent distribution moves (Henry Schein marketing, GI group pilots) are aimed at exactly this, but the pace of physician education and uptake is an open question. Guidance or early metrics (such as number of physicians ordering, tests processed per month, etc.) would be very informative if the company provides them in upcoming reports.

– Can Biomerica Reach Profitability Without Further Dilution? Management has publicly expressed optimism that current resources and revenue growth plans could carry the company to profitability (^[11]). Achieving true profitability (net income > $0) in 2026 would be a transformative milestone, but it is not guaranteed. It likely requires not only growing revenue, but also maintaining disciplined spending. Biomerica did implement cost-saving measures (reducing annual expenses by ~$1.0–1.4M via a workforce reduction and other cuts) in fiscal 2024 (^[8]) (^[8]). The question is whether these leaner operations, combined with higher-margin IBS test revenue, can indeed tip the company into the black. In Q1 FY2026, they essentially broke even thanks to a one-time tax credit (^[6]), but operationally were still slightly in the red. Investors will want to see if by late 2026 the gross profit from inFoods® IBS (plus other products) is enough to cover ~$1.5M quarterly operating expenses consistently. If not, Biomerica may need to raise capital in 2026/2027. The timing and method of any capital raise is an open question – will they attempt another public offering, tap the ATM facility again, or seek strategic partnerships for funding? For now, cash on hand might suffice, but only if the business ramps as hoped. No news on financing likely means things are on track; an unexpected equity raise would signal that uptake is slower or spending is higher than internal forecasts.

– What is the Status of Pipeline Products (H. pylori, etc.)? While inFoods® IBS is the flagship, Biomerica has other products in development that could contribute future value. One notable one is the hp+detect™ H. pylori test (a rapid device to detect H. pylori infections). The company was working with the FDA to get this test cleared; as of late 2023, one final data set was being submitted to the FDA (^[4]). An open question is whether and when the H. pylori test will receive FDA approval. If approved, Biomerica would have a new product to sell into a large market (H. pylori infects ~35% of the U.S. population (^[4])). They have hinted at discussions with major labs and distributors for this product (^[8]), so clearance could unlock partnerships and a new revenue stream. Similarly, Biomerica’s Fortel® line of at-home tests (for ulcers, kidney disease, PSA/prostate, etc.) has seen some international regulatory approvals (e.g. UAE, Saudi FDA) (^[6]) (^[8]). Will the company be able to capitalize on these by selling internationally, or find a U.S. retail channel for more of these tests (similar to how EZ Detect is sold in CVS/Walmart) (^[4])? Any progress on secondary products could diversify the revenue base and reduce reliance on the IBS test alone. Investors should watch for updates on the FDA submission and commercialization plans for hp+detect™, as well as any new distribution deals for the at-home test portfolio.

– Could Biomerica Become an Acquisition Target? Given Biomerica’s small size and the potential of inFoods® IBS, one strategic question is whether a larger diagnostics or life-science company might seek to acquire it. The test’s precision medicine approach in IBS could be attractive to companies in the GI space or to large lab companies if the concept gains momentum. There are precedents of big players buying innovative diagnostic startups once reimbursement and demand are evident. While there are no public indications of this yet, the possibility of M&A could grow if the test gains significant adoption. For shareholders, an acquisition at a premium would be an obvious upside scenario. This remains speculative, but worth pondering as the story develops.

In conclusion, Biomerica enters 2026 at a pivotal juncture. The $300 Medicare reimbursement rate for inFoods® IBS is a strong validation of the product’s value and removes a major uncertainty around pricing. Now the focus shifts to execution: converting this reimbursement win into actual test orders and insurance payments. The company’s fundamentals – no debt, controlled expenses, and a defined market need – provide a foundation, but the true test will be market traction. If Biomerica can achieve significant IBS test adoption, it could transform from a micro-cap into a growing, profitable diagnostic firm. If not, it may struggle to sustain itself given limited alternate revenue.

Stakeholders should keep an eye on the upcoming quarterly results and any corporate updates on reimbursement coverage or partnerships. These will offer clues to whether the inFoods® IBS commercialization is accelerating or facing hurdles. The next few quarters are thus critical for Biomerica’s long-term outlook. With high risk comes high reward potential: success in reaching even a fraction of IBS sufferers could multiply the company’s revenues (the IBS market is often cited as a $30+ billion opportunity) (^[4]), whereas shortfalls could lead to cash crunches or dilution. Biomerica’s recent accomplishments have positioned it at the starting line of a bigger race – one that will determine if the promise of precision diet therapy for IBS can indeed translate into shareholder value. The $300 Medicare boost is a big win on paper; the coming months will reveal how it translates into practice.

Sources

1. https://globenewswire.com/news-release/2025/12/23/3209862/0/en/Biomerica-Announces-CMS-Medicare-Payment-Rate-of-300-for-Revolutionary-inFoods-IBS-Test.html
2. https://za.investing.com/news/stock-market-news/biomerica-stock-soars-after-medicare-sets-300-payment-rate-for-ibs-test-93CH-4039732
3. https://finviz.com/news/260815/biomerica-announces-cms-medicare-payment-rate-of-300-for-revolutionary-infoods-ibs-test
4. https://investors.biomerica.com/news/news-details/2023/Biomerica-Reports-Fiscal-2023-Year-End-Results/default.aspx
5. https://globenewswire.com/news-release/2025/11/25/3194308/0/en/Biomerica-s-inFoods-IBS-Product-Featured-in-Biotherapeutics-Quarterly-a-Henry-Schein-Publication-Highlighting-a-New-Precision-Approach-for-Treating-IBS.html
6. https://investors.biomerica.com/news/news-details/2025/Biomerica-Reports-First-Quarter-Fiscal-2026-Financial-Results/default.aspx
7. https://stocktitan.net/news/BMRA/henry-schein-and-biomerica-enter-into-marketing-services-agreement-zpjyi5w3j48b.html
8. https://investors.biomerica.com/news/news-details/2024/Biomerica-Reports-First-Quarter-Fiscal-2025-Financial-Results/
9. https://sec.gov/Archives/edgar/data/73290/000149315223030254/form10-k.htm
10. https://biospace.com/biomerica-announces-pricing-of-8-million-underwritten-public-offering-of-common-stock
11. https://globenewswire.com/news-release/2023/10/13/2759856/0/en/Biomerica-Reports-First-Quarter-2024-Financial-Results.html
12. https://sec.gov/Archives/edgar/data/73290/000149315224014474/form10-q.htm
13. https://investors.biomerica.com/news/news-details/2025/Biomerica-Announces-Reverse-Stock-Split/default.aspx

For informational purposes only; not investment advice.